File Download

There are no files associated with this item.

Conference Paper: Characterization of extracellular secreted Epstein-Barr virus BART microRNAs as serological markers for nasopharyngeal carcinoma diagnosis and treatment

TitleCharacterization of extracellular secreted Epstein-Barr virus BART microRNAs as serological markers for nasopharyngeal carcinoma diagnosis and treatment
Authors
Issue Date2014
Citation
The 16th International Symposium on EBV and Associated Diseases, Brisbane, Australia, 16-19 July 2014 How to Cite?
AbstractNasopharyngeal carcinoma (NPC) exhibits a distinct geographical and ethnic distribution. It is recognized that 75-90% of NPC patients have already developed local or regional spread at diagnosis, which hampers effective treatment and results in a poor prognosis. It is essential to characterize more sensitive and specific biomarkers for NPC screening of high risk individuals and for differentiation of treatment options upon diagnosis. One of the hallmarks of NPC is the ubiquitous association with Epstein-Barr virus (EBV). In NPC cells, EBV expresses only very essential viral proteins, but more than 20 BART microRNAs (miRNAs) at abundant levels. This study characterized NPC specific BART miRNAs through a comprehensive analysis of EBV BART microRNA expression profiles in EBV infected cells, including latency I and III EBV infected BL cells, EBV transformed LCLs, EBV-harbouring NPC cells and non-cancerous nasopharyngeal cells. We further characterized the BART miRNAs secreted into culture supernatants and determined that BART-3, BART-7 and BART-13 miRNAs are regularly secreted into the extracellular environment, implicating these BART miRNAs as potential serological biomarkers for use in NPC screening. Analysis of plasma specimens obtained from NPC patients and healthy and non-NPC tumor patient controls found levels of both BART-7 and BART-13 to be significantly higher among NPC patients, with elevated levels being particularly apparent among patients with advanced disease. Levels of BART-3 were indistinguishable between NPC and control groups. We further confirmed that BART-7 and BART-13 are NPC associated. Analysis of 41 NPC patients before and after successful radiotherapy treatment showed that BART-7 and BART-13, but not BART-3, were diminished after treatment. Receiver Operating Characteristic (ROC) curve analysis combining BART-7 and BART-13 levels produces a 90% predictive value for the presence of NPC. These results indicate that BART-7 and BART-13 may be useful new serological biomarkers for diagnosis of NPC and prediction of treatment efficacy.
DescriptionCelebrating 50 years of Epstein-Barr virus discovery (1964-2014)
Session III: Nasopharyngeal Carcinoma – Population studies and emerging therapies
Persistent Identifierhttp://hdl.handle.net/10722/203723

 

DC FieldValueLanguage
dc.contributor.authorZhang, Gen_US
dc.contributor.authorZong, Jen_US
dc.contributor.authorVerhoeven, RJAen_US
dc.contributor.authorTong, Sen_US
dc.contributor.authorJi, Men_US
dc.contributor.authorCheng, Wen_US
dc.contributor.authorLung, MLen_US
dc.contributor.authorTsao, GSWen_US
dc.contributor.authorPan, Jen_US
dc.contributor.authorChen, Hen_US
dc.date.accessioned2014-09-19T16:11:30Z-
dc.date.available2014-09-19T16:11:30Z-
dc.date.issued2014en_US
dc.identifier.citationThe 16th International Symposium on EBV and Associated Diseases, Brisbane, Australia, 16-19 July 2014en_US
dc.identifier.urihttp://hdl.handle.net/10722/203723-
dc.descriptionCelebrating 50 years of Epstein-Barr virus discovery (1964-2014)-
dc.descriptionSession III: Nasopharyngeal Carcinoma – Population studies and emerging therapies-
dc.description.abstractNasopharyngeal carcinoma (NPC) exhibits a distinct geographical and ethnic distribution. It is recognized that 75-90% of NPC patients have already developed local or regional spread at diagnosis, which hampers effective treatment and results in a poor prognosis. It is essential to characterize more sensitive and specific biomarkers for NPC screening of high risk individuals and for differentiation of treatment options upon diagnosis. One of the hallmarks of NPC is the ubiquitous association with Epstein-Barr virus (EBV). In NPC cells, EBV expresses only very essential viral proteins, but more than 20 BART microRNAs (miRNAs) at abundant levels. This study characterized NPC specific BART miRNAs through a comprehensive analysis of EBV BART microRNA expression profiles in EBV infected cells, including latency I and III EBV infected BL cells, EBV transformed LCLs, EBV-harbouring NPC cells and non-cancerous nasopharyngeal cells. We further characterized the BART miRNAs secreted into culture supernatants and determined that BART-3, BART-7 and BART-13 miRNAs are regularly secreted into the extracellular environment, implicating these BART miRNAs as potential serological biomarkers for use in NPC screening. Analysis of plasma specimens obtained from NPC patients and healthy and non-NPC tumor patient controls found levels of both BART-7 and BART-13 to be significantly higher among NPC patients, with elevated levels being particularly apparent among patients with advanced disease. Levels of BART-3 were indistinguishable between NPC and control groups. We further confirmed that BART-7 and BART-13 are NPC associated. Analysis of 41 NPC patients before and after successful radiotherapy treatment showed that BART-7 and BART-13, but not BART-3, were diminished after treatment. Receiver Operating Characteristic (ROC) curve analysis combining BART-7 and BART-13 levels produces a 90% predictive value for the presence of NPC. These results indicate that BART-7 and BART-13 may be useful new serological biomarkers for diagnosis of NPC and prediction of treatment efficacy.en_US
dc.languageengen_US
dc.relation.ispartofInternational Symposium on EBV and Associated Diseasesen_US
dc.titleCharacterization of extracellular secreted Epstein-Barr virus BART microRNAs as serological markers for nasopharyngeal carcinoma diagnosis and treatmenten_US
dc.typeConference_Paperen_US
dc.identifier.emailLung, ML: mlilung@hku.hken_US
dc.identifier.emailTsao, GSW: gswtsao@hku.hken_US
dc.identifier.emailChen, H: hlchen@hku.hken_US
dc.identifier.authorityLung, ML=rp00300en_US
dc.identifier.authorityTsao, GSW=rp00399en_US
dc.identifier.authorityChen, H=rp00383en_US
dc.identifier.hkuros240050en_US
dc.identifier.hkuros246889-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats